Advances in In Silico Study of Generic Orally Inhaled Drug Products

Authored by: Hao Miao , Renjie Li , Xudong Zhou , Jiaqi Yu , Fen Huang , Haoqin Yang , Zhenbo Tong

Handbook of Lung Targeted Drug Delivery Systems

Print publication date:  October  2021
Online publication date:  October  2021

Print ISBN: 9780367490676
eBook ISBN: 9781003046547
Adobe ISBN:


 Download Chapter



Orally inhaled drug products (OIDPs) refer to a drug-device system in which drugs in the form of aerosols, powders, solutions, or suspensions are delivered into the lung via oral inhalation (1). An OIDP usually consists of two components, the drug formulation and an inhaler device which allows the administration of the drug and the deposition of active ingredients in the targeted site within patients. OIDPs show great capability of therapeutic effectiveness to treat pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and asthma (2), as well as systemic diseases, such as diabetes (3), schizophrenia (4), and Parkinson’s disease (5). Based on inhalation method, OIDPs are categorized into pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) and the newly developed soft mist inhalers (SMIs).

Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.